Datapoint: Keytruda Scores First-Line Esophageal Cancer Nod

The FDA last week approved Merck & Co.’s Keytruda for the treatment of newly diagnosed esophageal or gastroesophageal junction carcinoma in tandem with chemotherapy. Keytruda is the first PD-1/L1 agent to be approved as a first-line therapy for this type of cancer. The drug was approved as a third-line treatment for gastric or gastroesophageal junction cancer in 2017, an indication where it holds preferred formulary placement for 6% of covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 3/24/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today